+39 02 610346.1 - info@newron.com



Newron AGM Result and Clinical and Business Update


Newron updates on STARS study FDA interaction


Newron announces 2019 financial results and provides outlook for 2020


Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia


Newron Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference in New York

Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA